Corcept Therapeutics Incorporated (CORT) Faces Securities Fraud Investigation

The Law Offices of Frank R. Cruz have initiated an investigation into Corcept Therapeutics Incorporated (referred to as “Corcept” or the “Company”) (NASDAQ: CORT) on behalf of investors to look into potential violations of federal securities laws.

Following the announcement made on December 31, 2025, by Corcept regarding the U.S. Food and Drug Administration (FDA) issuing a Complete Response Letter (CRL), the stock price of the Company experienced a significant decline. The CRL detailed the rejection of the Company’s New Drug Application (NDA) for relacorilant, intended as a treatment for hypertension secondary to hypercortisolism. Corcept expressed surprise and disappointment at the FDA’s decision, resulting in a $35.40 decrease per share or 50.42% drop in the stock price, closing at $34.80 per share on December 31, 2025.

Subsequently, on January 29, 2026, the FDA released an updated CRL concerning Corcept’s relacorilant NDA. In the newly disclosed letter, it was revealed that the FDA had, on several occasions during pre-submission meetings, raised concerns with Corcept regarding the adequacy of the clinical development program to evaluate the impact of relacorilant and cautioned the Company to anticipate significant review issues should they submit their application. Following this update, Corcept’s stock price experienced a further decline of $4.71 per share or 10.6%, closing at $39.87 per share on January 30, 2026, leading to losses for investors.

Investors who have suffered losses as a result of holding Corcept securities and wish to explore potential legal recourse or need more information regarding the matter are encouraged to reach out to The Law Offices of Frank R. Cruz. The firm can be contacted at their Century City, California location. By contacting the office, investors can inquire about participating in the case, seeking clarification on the claims, or addressing any queries they may have concerning their rights or concerns related to these developments.

In conclusion, the investigation into Corcept Therapeutics Incorporated by The Law Offices of Frank R. Cruz aims to address potential violations of federal securities laws and shed light on the recent events that have impacted the Company’s stock price, causing financial losses to investors. Investors are urged to take action by contacting the law firm to explore their options and seek guidance on how to proceed in response to these developments.